Safety Groups Sound Alarm on FDA Peptide Compounding Vote

Safety groups are sounding alarms after the FDA’s Pharmacy Compounding Advisory Committee recommended six of seven peptides for the section 503A compounding list at its July 23-24 meeting — a decision trade press says still worries experts over weak evidence, dosing, sterility, and oversight risks in compounding pharmacies. The Specialty Pharmacy Continuum report published August 26 said the recommendations “alarm safety experts,” and the concerns echo the independent watchdog warnings issued before the FDA announced the meeting in April.

The Panel’s Narrow Vote

Over two days at FDA’s White Oak campus in Silver Spring, Maryland, PCAC recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulks List — the “positive list” of bulk ingredients traditional compounding pharmacies may use — and declined to recommend Emideltide, also known as DSIP.

The margins were close, according to published meeting coverage: BPC-157 passed 8-6 with one abstention, KPV 8-6, TB-500 8-6, MOTS-c 7-5 with two abstentions, Semax 8-5, and Epitalon 7-4. DSIP failed 6-7 with one abstention.

Why Safety Groups Are Alarmed

The alarm is not new. In May, ECRI and the Institute for Safe Medication Practices released a joint white paper concluding that patients using compounded wellness peptides have “no reliable source of information” about whether the products work or are safe. The organizations found that 35 of 36 published studies of BPC-157 were conducted only in animals, and that independent testing of gray-market products showed purity ranging from 5% to 75%, with arsenic and lead contamination exceeding limits for sterile injectable drugs.

“The commercial market for these compounded peptides has grown far faster than the science,” Rita Jew, president of ISMP, said in a statement accompanying the white paper. “Patients are injecting substances that have never been adequately tested in humans, based on marketing claims the available evidence simply does not support.”

The August 26 Specialty Pharmacy Continuum report frames the same concerns around the panel’s decision specifically: experts worry the recommendations rest on weak evidence and that 503A pharmacies may lack the sterility controls and oversight needed to compound injectable peptides at scale. PeptidesBeat covered the watchdog warning when it was released in May.

FDA Staff Objected to All Seven

The committee’s recommendations overrode the objections of FDA’s own reviewers, who opposed all seven nominations. Published accounts of the meeting say staff briefings cited near-absent human clinical trial data across the class, immunogenicity and anti-drug antibody risks for BPC-157, and World Anti-Doping Agency prohibition flags for TB-500 and MOTS-c. The panel’s votes came after a June reconstitution of the PCAC roster that published analysis ties to the Department of Health and Human Services’ deregulatory push — a shift PeptidesBeat analyzed ahead of the meeting.

The Vote Changes Nothing Yet

The PCAC vote is advisory and non-binding. Adding a substance to the 503A Bulks List requires formal notice-and-comment rulemaking published in the Federal Register, and analysts put a realistic timeline for any final regulation in 2027 at the earliest. The compounds also remain unapproved for the uses FDA evaluated — ulcerative colitis and wound healing for BPC-157 and TB-500, obesity and osteoporosis for MOTS-c, insomnia for Epitalon — and no vote changes their investigational status.

A second PCAC meeting to consider additional bulk nominations is expected before February 2027, which would cover remaining reclassified peptides such as GHK-Cu.

What to Watch

The contrast with the agency’s enforcement posture is sharp. While PCAC recommended these six peptides for 503A compounding, the FDA has simultaneously pushed to exclude compounded GLP-1 drugs from legal compounding after shortages resolved — a push the Fifth Circuit ratified on Aug 27, 2026, when it upheld the FDA’s GLP-1 delisting: bulk compounding of semaglutide and tirzepatide for general use is no longer lawful, while patient-specific 503A compounding for documented medical needs remains legal. Industry observers expect the agency to keep enforcing against unapproved peptide products during the rulemaking window, even as the advisory path toward legal compounding slowly moves forward.

Why This Matters

The July vote was the first time the FDA’s compounding advisory body recommended wellness peptides for the bulk list, but the gap between marketing claims and clinical evidence remains exactly where ECRI and ISMP said it was in May. Until a final rule lands, the practical situation is unchanged: the peptides are not approved, not on the bulk list, and not verifiable when purchased outside regulated channels. Safety groups want the public to understand that a non-binding advisory vote is not a safety endorsement — a point that applies with equal force to the six recommended compounds and the one rejected.

Nothing in this article is medical advice. The peptides discussed are not FDA-approved for the uses evaluated and remain investigational.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.